Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
SAN DIEGO and TORONTO, March 14, 2016 -- Aptose Biosciences Inc. (Aptose) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, will release its financial results for the quarter and year ended December 31, 2015, on Tuesday, March 29, 2016 after the close of the market. The company intends to host a conference call on the same day at 5:00 p.m. ET to discuss the financial results.
Participants can access the conference call by dialing (855) 546-9557 (North American toll free number) and (412) 455-6106 (International dial in) and using passcode 62005139. The conference call can also be accessed at http://edge.media-server.com/m/p/bo22ksf9 and will also be available through a link on the Investor Relations section of Aptose’s website at ir.aptose.com. Please log onto the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required. An archived version of the webcast along with a transcript will be available on the company’s website for 30 days. An audio replay of the webcast will be available approximately two hours after the conclusion of the call for 7 days by dialing 1-855-859-2056, using the passcode 62005139.
The press release, the financial statements and the management’s discussion and analysis for the quarter ended and year ended December 31, 2015 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed to provide additive or synergistic efficacy with existing anti-cancer therapies and regimens without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS. For further information, please visit www.aptose.com.
For further information, please contact: Aptose Biosciences Greg Chow, CFO 647-469-9828 [email protected] BCC Partners Karen L. Bergman or Susan Pietropaolo 650-575-1509 or 845-638-6290 [email protected] or [email protected]
